Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Phase 3CompletedNCT01071915

Ferring Pharmaceuticals157 enrolled

Overview

This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

157

Conditions

Prostate Cancer

Interventions

Degarelix 240/80 mgDRUG

The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has given written informed consent before any trial-related activity is performed. * Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages) (except for neoadjuvant hormonal therapy/ includes patients with rising PSA after prostatectomy or radiotherapy) * Is a male patient aged 18 years or older * Has a screening serum testosterone level \>1.5 ng/mL * Has an ECOG (Eastern Cooperative Oncology Group) score of ≤ 2 * Has a screening PSA value of ≥2 ng/mL * Has a life expectancy of at least 12 months Exclusion Criteria: * Has had previous or is currently under hormonal management of prostate cancer. However, prostatectomy or radiotherapy with curative intention, neoadjuvant/adjuvant hormonal therapy are accepted for a maximum duration of 6 months, at least 6 months prior to Screening Visit * Is currently treated with a 5-α-reductase inhibitor * Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy * Has a history of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema * Has hypersensitivity towards any component of the investigational medicinal product * A marked baseline prolongation of QT/QTcF interval * A history of additional risk factors for Torsade de Pointes ventricular arrhythmias * Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin * Has a known or suspect hepatic, symptomatic biliary disease * Has elevated serum ALT level more than the upper limit of normal or serum total bilirubin level above the upper level of normal range at the Screening Visit and confirmed with a second measurement within 21 days * Has other clinically significant laboratory abnormalities * Has a clinically significant disorder (other than prostate cancer) or any other condition, including alcohol or drug abuse * Has a mental incapacity or language barriers precluding adequate understanding or co- operation * Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial * Has previously participated in any degarelix trial

Locations (11)

Kyoungbuk National University Hospital

Daegu, Daegu, South Korea

Hallym University Sacred Heart Hospital

Pyungchon, Gyunggi-do, South Korea

Pusan National University Yangsan Hospital

Mulgeum-eup, Gyungnam, South Korea

Outcomes

Primary Outcomes

Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196

Time frame: Day 28 to Day 196

Secondary Outcomes

Proportion of Patients With Testosterone Level ≤0.5 ng/mL at Day 3

Time frame: At day 3

Percentage Change in Prostate-specific Antigen (PSA) From Baseline to Day 28

Time frame: To Day 28

Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL)From Day 56 to Day 196

Time frame: Day 56 to Day 196

Cumulative Probability of no PSA Failure From Day 28 to Day 196

PSA failure was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir.

Time frame: To Day 196

Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables

The figures present the number of participants who had markedly abnormal levels of safety laboratory variables. Only the laboratory variables that had at least one percentage of participants in either group with abnormal value are presented, more variables were included in the study.

Time frame: To Day 196

Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight

This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.

Time frame: To Day 196

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.